<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821310</url>
  </required_header>
  <id_info>
    <org_study_id>B1791094</org_study_id>
    <secondary_id>2020-005030-15</secondary_id>
    <nct_id>NCT04821310</nct_id>
  </id_info>
  <brief_title>Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years</brief_title>
  <official_title>AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE ESOPHAGITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the outcomes, tolerability and safety of 2 different&#xD;
      doses of oral pantoprazole (full healing dose, half healing dose), assigned based upon&#xD;
      weight, for the maintenance of healing of erosive esophagitis in pediatric participants aged&#xD;
      1 to 17 years with endoscopically-confirmed, healed erosive esophagitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explore the outcomes, tolerability and safety of 2 different doses of oral pantoprazole (full&#xD;
      healing dose, half healing dose), assigned based upon weight, for the maintenance of healing&#xD;
      of erosive esophagitis in pediatric participants aged 1 to 17 years with&#xD;
      endoscopically-confirmed, healed erosive esophagitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">December 9, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24, considering patients with excessive use of rescue medication as treatment failures</measure>
    <time_frame>Week 24</time_frame>
    <description>Endoscopically confirmed maintenance of healing of erosive esophagitis at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Physical Examinations and Vital Signs</measure>
    <time_frame>Baseline up to 36 weeks</time_frame>
    <description>Safety and tolerability will be assessed by physical examinations, blood pressure, and pulse rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Baseline up to 36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in Laboratory Tests Results</measure>
    <time_frame>Baseline up to 36 weeks</time_frame>
    <description>Safety and tolerability will be assessed by clinical laboratory measurements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Esophagitis</condition>
  <arm_group>
    <arm_group_label>Arm 1 Full Dose Pantoprazole and matching placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full Healing Dose of pantoprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Half Dose Pantoprazole and matching placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half Healing Dose of pantoprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full dose Pantoprazole plus matching placebo</intervention_name>
    <description>Full healing dose of pantoprazole plus matching placebo</description>
    <arm_group_label>Arm 1 Full Dose Pantoprazole and matching placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half Dose Pantoprazole plus matching placebo</intervention_name>
    <description>Half healing dose of pantoprazole plus matching placebo</description>
    <arm_group_label>Arm 2 Half Dose Pantoprazole and matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a documented erosive lesion with an Los Angeles (LA) Grade of A&#xD;
             to D prior to starting Proton Pump Inhibitor treatment:&#xD;
&#xD;
          -  Capable of giving signed informed consent/assent&#xD;
&#xD;
          -  Willingness and ability of the participant or parent/legal guardian to complete the&#xD;
             eDiary&#xD;
&#xD;
          -  Willing and able to comply with all scheduled visits, treatment plan, laboratory&#xD;
             tests, lifestyle considerations, and other study procedures, including the use of the&#xD;
             eDiary.&#xD;
&#xD;
          -  Male and female participants aged 1 to 17 years.&#xD;
&#xD;
          -  Minimum body weight 7 kilogram and weight at least at the 5th percentile per the&#xD;
             Center for Disease Control standard age and weight chart, for the participant's age.&#xD;
&#xD;
          -  To be considered a female of non childbearing potential, the participant must meet at&#xD;
             least 1 of the following criteria :&#xD;
&#xD;
          -  Premenarchal: The investigator (or other appropriate staff) must discuss the&#xD;
             participant's premenarchal status with the participant and parent/legal guardian at&#xD;
             office visits and during telephone contacts, as participants who achieve menarche&#xD;
             during the study would no longer be considered &quot;female participants of non&#xD;
             childbearing potential&quot; and must comply with the protocol requirements applicable to&#xD;
             women of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous administration of an investigational drug or vaccine within 30 days (or as&#xD;
             determined by the local requirement) or 5 half-lives preceding the first dose of study&#xD;
             intervention used in this study (whichever is longer).&#xD;
&#xD;
          -  Children that may be at high risk from procedural sedation should be carefully&#xD;
             evaluated. Participants with a history of complications during prior procedural&#xD;
             sedation&#xD;
&#xD;
          -  History or presence of upper gastrointestinal anatomic or motor disorders&#xD;
&#xD;
          -  Family history of malignant hyperthermia&#xD;
&#xD;
          -  Known hypersensitivity to any Proton Pump Inhibitor, including pantoprazole or to any&#xD;
             substituted benzimidazole or to any of the excipients.&#xD;
&#xD;
          -  Any disorder requiring chronic (daily) use of warfarin, heparin, other anticoagulants,&#xD;
             methotrexate, atazanavir or nelfinavir, clopidogrel, or potent inhibitors or inducers&#xD;
             of CYP2C19 (eg, phenytoin, sulfamethoxazole, valproic acid, carbamazepine, and&#xD;
             griseofulvin).&#xD;
&#xD;
          -  Serum creatine kinase levels &gt;3 x upper limit of normal.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus or clinical manifestations of acquired&#xD;
             immune deficiency syndrome.&#xD;
&#xD;
          -  Active malignancy of any type, or history of a malignancy. Participants with a history&#xD;
             of malignancies that have been surgically removed or eradicated by irradiation or&#xD;
             chemotherapy and who have no evidence of recurrence for at least 5 years before&#xD;
             Screening are acceptable.&#xD;
&#xD;
          -  Diagnosed as having or has received treatment for esophageal, gastric, pyloric&#xD;
             channel, or duodenal ulceration within 30 days before the Screening visit.&#xD;
&#xD;
          -  Alanine aminotransferase or blood urea nitrogen &gt;2.0 upper limit of normal or&#xD;
             estimated creatinine &gt;1.5 X upper limit of normal for age or any other laboratory&#xD;
             abnormality considered by the Investigator to be clinically significant within 14 days&#xD;
             before the Baseline Visit (Day 1).&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or study intervention&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the participant inappropriate for entry into&#xD;
             this study.&#xD;
&#xD;
          -  Has, in the Investigator's opinion, a serious chronic condition (eg, diabetes,&#xD;
             epilepsy), which is either not stable or not well controlled and may interfere with&#xD;
             the conduct of the study.&#xD;
&#xD;
          -  Has any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
        Prior or Concomitant Therapy:&#xD;
&#xD;
          -  Frequent, repeated use of oral or parenteral glucocorticoids (eg, prednisone,&#xD;
             prednisolone, dexamethasone). Steroid inhalers and topical steroids may be used.&#xD;
&#xD;
          -  Pregnant female participants; breastfeeding female participants.&#xD;
&#xD;
          -  Is unwilling or unable to comply with the Lifestyle Considerations section&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Childrens Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabell Huntington Hospital Endoscopy Suite (Endoscopy Only)</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians and Surgeons, Inc dba Marshall Health</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University clinical center of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hospitals</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD Imedi Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Clinic after G. Zhvania</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgian-American Family Medicine Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0171</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evex clinic after I. Tsitsishvili</name>
      <address>
        <city>Tbilisi</city>
        <zip>Georgia</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heim Pal Pediatric Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital HIMA San Pablo Caguas</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caribbean Clinical Research, LLC</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1791094</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erosive</keyword>
  <keyword>esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

